Detalhe da pesquisa
1.
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.
Haematologica
; 108(9): 2444-2453, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815381
2.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731259
3.
Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Intern Med J
; 52(9): 1609-1623, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34532916
4.
Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Intern Med J
; 51(12): 2119-2128, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34505342
5.
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.
Intern Med J
; 50(6): 667-679, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32415723
6.
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Hematol Oncol
; 37(3): 253-260, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30983008
7.
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Blood Adv
; 8(7): 1639-1650, 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38315878
8.
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
J Clin Oncol
; 41(33): 5099-5106, 2023 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37478390
9.
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).
Leuk Lymphoma
; 62(2): 368-376, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33140664
10.
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
Blood Adv
; 4(23): 6009-6018, 2020 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33284944